Showing 5771-5780 of 9770 results for "".
- Milestone Scientific Set To Launch New Botox Delivery Instrumenthttps://practicaldermatology.com/news/milestone-scientific-set-to-launch-new-botox-delivery-instrument/2457965/Botulinum toxin injections may be about to get smarter and more comfortable as Milestone Scientific Inc. gears up to launch its novel and proprietary cosmetic injection instrument. The new cosmetic injection instrument allows the clinician
- Psoriasis Severity Linked to Diabetes Riskhttps://practicaldermatology.com/news/psoriasis-severity-linked-to-diabetes-risk/2457970/Psoriasis patients are more likely to develop Type 2 diabetes than their psoriasis-free counterparts, and this risk increases dramatically based on the severity of the disease, according to researchers from the Perelman School of Medicine at the University of
- Sonoma Pharmaceuticals Launches Loyonhttps://practicaldermatology.com/news/sonoma-pharmaceuticals-launches-loyon/2457971/Sonoma Pharmaceuticals, Inc. has begun US commercialization of the company’s new Loyon® product. Under the supervision of a healthcare practitioner, Loyon is intended to manage and relieve the scaling, erythema, and itching associated with various types of dermatoses including seborrhea
- Long-Term Use of Lilly's Taltz Shows Efficacy Improvements in PsA for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitorshttps://practicaldermatology.com/news/long-term-use-of-lillys-taltz-shows-efficacy-improvements-in-psa-for-patients-with-prior-inadequate-response-or-intolerance-to-tnf-inhibitors/2457980/Patients with active psoriatic arthritis (PsA) treated with Taltz (ixekizumab), who were previously intolerant or had inadequate responses to TNF inhibitors, showed improvements in the signs and symptoms of PsA across treatment groups for up to 52 weeks, according to Eli Lilly and Company. Interi
- DermTech Adds Dr. Harold Rabinovitz to Scientific Advisory Boardhttps://practicaldermatology.com/news/dermtech-adds-harold-rabinovitz-to-scientific-advisory-board/2457982/DermTech, Inc., appointed Harold Rabinovitz, MD to its Scientific Advisory Board. Dr. Rabinovitz is a Board Certified Dermatologist and a voluntary Clinical Professor of Dermatology at University of Miami School of Medicine. He is world-renown for his work in dermoscopy and confocal microscopy.</
- Possible Eczema Breakthrough? S. aureus May Promote Skin Inflammation via IL-36-Mediated T Cell Responseshttps://practicaldermatology.com/news/possible-eczema-breakthrough-s-aureus-may-promotes-skin-inflammation-via-il-36-mediated-t-cell-responses/2457978/Toxin-producing bacteria on the surface of our skin may induce a protein that causes our own cells to react and cause inflammation, according to research published online in Cell Host & Microbe. <
- Study: PsO, RA Patients Prescribed Similar Drugs, But PsO Patients Face Higher Liver Disease Riskhttps://practicaldermatology.com/news/study-pso-ra-patients-prescribed-similar-drugs-yet-pso-patients-face-higher-liver-disease-risk/2457987/Compared to controls, patients with psoriasis (PsO) are at higher risk for serious liver disease than patients with rheumatoid arthritis, reports a in the Journal of Investigative Dermatology from researchers a
- Sensus Healthcare Launches SRT-100 for Keloid Prevention and Treatment in Chinahttps://practicaldermatology.com/news/sensus-healthcare-launches-srt-100-in-china-for-keloid-prevention-and-treatment/2457985/Sensus Healthcare, Inc. launched the SRT-100™ in China for the treatment and prevention of keloids with Chindex Medical Limited. Sensus also announced the extension of its exclusive distribution agreement with Chindex M
- FDA Accepts Ortho Dermatologic's NDA for Novel Plaque Psoriasis Treatment, IDP-118https://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-nda-for-novel-plaque-psoriasis-treatment-idp-118/2457988/The US Food and Drug Administration has accepted Ortho Dermatologic's New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date i
- Long-Term Fat Reduction Seen Following Treatment with BTL Vanquish, Vanquish MEhttps://practicaldermatology.com/news/long-term-fat-reduction-seen-following-treatment-with-btl-vanquish-vanquish-me/2457992/Abdominal fat reduction achieved via BTL Vanquish and Vanquish ME lasts for at least four years, according to new long-term data released by the company. Both devices use radiofrequency (RF) energy to reduce fat. The study evaluated 13 in